Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program.

Fiche publication

Date publication

mai 2019

Journal

International journal of cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Dr EYMARD Jean-Christophe , Pr PETIT Thierry

Tous les auteurs :
Jacot W, Heudel PE, Fraisse J, Gourgou S, Guiu S, Dalenc F, Pistilli B, Campone M, Levy C, Debled M, Leheurteur M, Chaix M, Lefeuvre C, Goncalves A, Uwer L, Ferrero JM, Eymard JC, Petit T, Mouret-Reynier MA, Courtinard C, Cottu P, Robain M, Mailliez A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/31087564

Résumé

Eribulin mesylate (EM) was recently approved for metastatic breast cancer (MBC) chemotherapy in late lines by the FDA, with debated results in 2 line. We evaluated outcomes in breast cancer patients receiving EM as second, third and fourth line in a national real-life cohort of 16,703 consecutive MBC patients initiating their first metastatic therapeutic line between 2008 and 2014. Primary and secondary objectives were overall survival (OS) and progression-free (PFS). An imbalance was seen for HER2+ tumors and concomitant anti-HER2 targeted therapies use, we thus performed a sub-analysis in HER2- patients. PFS and OS were significantly better in EM patients in 3 and 4 lines, compared to "Other chemotherapies" patients (PFS: 4.14 vs. 3.02 months, p=0.0010; 3.61 vs. 2.53 months, p=0.0102, 3 and 4 -line; OS: 11.27 vs. 7.65 months, p=0.0001; 10.91 vs. 5.95 months, p<0.0001, 3 and 4 -line). No significant difference was reported in 2 -line (PFS: 5.06 vs. 4.14 months, p=0.1171; OS: 13.99 vs. 11.66 months, p=0.151). Among HER2- patients, a significant difference was seen for all lines, including 2 -line (PFS: 4.57 vs. 3.91 months, p=0.0379; OS: 14.98 vs. 10.51 months, p=0.0113). In this large real-world database, HER2-negative MBC patients receiving EM in 2 or later chemotherapy line presented significantly better PFS and OS. This difference disappeared in 2 line in the overall population, probably because of the imbalance in HER2-targeted treatments use. Our results mirror those of the published randomized trials. The effect of anti-HER2 therapies addition in this setting still needs to be defined. This article is protected by copyright. All rights reserved.